regulatory landscape

FDA category status, WADA prohibited list, compounding pharmacy rules, and international legal frameworks

Legal Gray Zones

TB-500 occupies a complex regulatory position. it is not FDA-approved for any human use and is banned by WADA in competitive sports. yet it is not a scheduled controlled substance in most countries, and it remains available from research chemical suppliers. the FDA's 2023 decision to add thymosin alpha-1 and thymosin beta-4 to the "do not compound" list further restricted access through compounding pharmacies -- the one channel that had provided some quality oversight.

Interactive Regulatory Comparison

Compare TB-500's regulatory status across jurisdictions and agencies.

regulatory status comparison

Knowledge Check

Test what you've learned in this unit.

Practice Exercises

Reinforce your understanding.